axis healthcare semaglutide Therapy Changes CT Body Composition Semaglutide dose may matter more

Market & industry impact: This launch could: Expand the GLP-1 market beyond injectables Trigger oral obesity drug race among pharma giants Influence nutraceutical & wellness industries Shift focus toward preventive metabolic care From a 13+ yrs Pharma & Cosmetics industry perspective: We are witnessing a transition where: Obesity is no longer just a lifestyle issue - its a pharmacologically managed chronic condition And oral GLP-1s like Foundayo could be the inflection point

This unique administration route is particularly appealing to patients who are averse to injections or those looking for the simplest integration into their daily routine

These adipose tissue alterations play a central role in the development of systemic insulin resistance, ectopic lipid accumulation, and cardiometabolic complications

Find articles by Donahue, L

For a look at how semaglutide results compare, TrimRx has a detailed breakdown of semaglutide timelines as well